RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-7.93%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$973M
AUM Growth
+$973M
(-21%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-14.06%
Top 10 Holdings %
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$13.1M |
| 2 |
Cigna
CI
|
$10.1M |
| 3 |
Biogen
BIIB
|
$8.66M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$6.47M |
| 5 |
Humana
HUM
|
$6.15M |
Top Sells
| 1 |
Natera
NTRA
|
$17M |
| 2 |
Becton Dickinson
BDX
|
$14.7M |
| 3 |
Boston Scientific
BSX
|
$13M |
| 4 |
HCA Healthcare
HCA
|
$12.6M |
| 5 |
Glaukos
GKOS
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Boston Scientific
BSX
$156B
| $39.7M | 4.08% | 444,000 -146,000 | -25% | -$13M |
|
2
Eli Lilly
LLY
$657B
| $35.1M | 3.61% | 45,450 -2,050 | -4% | -$1.58M |
|
3
Procept Biorobotics
PRCT
$2.23B
| $33.8M | 3.48% | 420,345 -24,655 | -6% | -$1.99M |
|
4
Intuitive Surgical
ISRG
$170B
| $33.4M | 3.43% | 64,000 +1,000 | +2% | +$522K |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $31M | 3.18% | 43,457 +4,457 | +11% | +$3.17M |
|
6
UnitedHealth
UNH
$281B
| $30.6M | 3.15% | 60,530 -12,170 | -17% | -$6.16M |
|
7
Inspire Medical Systems
INSP
$2.77B
| $27.8M | 2.86% | 150,041 +28,041 | +23% | +$5.2M |
|
8
Merck
MRK
$210B
| $27.6M | 2.84% | 277,500 +36,500 | +15% | +$3.63M |
|
9
Exact Sciences
EXAS
$8.98B
| $26.5M | 2.72% | 471,000 +6,000 | +1% | +$337K |
|
10
Tenet Healthcare
THC
$16.3B
| $25M | 2.57% | 197,700 -23,700 | -11% | -$2.99M |
|
11
Gilead Sciences
GILD
$140B
| $23.6M | 2.43% | 255,500 -111,000 | -30% | -$10.3M |
|
12
AbbVie
ABBV
$372B
| $22.1M | 2.27% | 124,150 -52,850 | -30% | -$9.39M |
|
|
13
Cigna
CI
$80.3B
| $21.6M | 2.22% | 78,385 +36,700 | +88% | +$10.1M |
|
14
Medtronic
MDT
$119B
| $21.5M | 2.21% | 269,500 -98,500 | -27% | -$7.87M |
|
15
Vertex Pharmaceuticals
VRTX
$100B
| $20.1M | 2.07% | 50,000 +2,250 | +5% | +$906K |
|
16
Alignment Healthcare
ALHC
$3.24B
| $19.8M | 2.04% | 1,761,192 -216,171 | -11% | -$2.43M |
|
|
17
Natera
NTRA
$23.1B
| $19.5M | 2.01% | 123,410 -107,590 | -47% | -$17M |
|
18
McKesson
MCK
$85.4B
| $19.4M | 2% | 34,117 +4,000 | +13% | +$2.28M |
|
|
19
Biogen
BIIB
$19.4B
| $18.9M | 1.94% | 123,700 +56,600 | +84% | +$8.66M |
|
20
Oscar Health
OSCR
$4.31B
| $18.3M | 1.88% | 1,362,421 -8,726 | -0.6% | -$117K |
|
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $17.9M | 1.84% | 145,500 +52,500 | +56% | +$6.47M |
|
22
BioMarin Pharmaceuticals
BMRN
$11.2B
| $16.5M | 1.69% | 250,623 -113,877 | -31% | -$7.49M |
|
23
Royalty Pharma
RPRX
$15.6B
| $15.2M | 1.56% | 595,000 -18,500 | -3% | -$472K |
|
24
Insulet
PODD
$23.9B
| $14.9M | 1.53% | 57,000 +17,000 | +43% | +$4.44M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14.7M | 1.51% | 176,000 -29,500 | -14% | -$2.46M |
|